US6403571B2
Expired / Lapsed
US
⏱️ 0.0 years remaining
Combination therapy for reducing the risks associated with cardiovascular disease
Assignee: Merck and Co Inc
•
Filing: 2001-01-18
•
Granted: 2002-06-11
•
Expires: 2021-01-18
Abstract
Abstract The instant invention involves a combination therapy and pharmaceutical compositions comprised of a therapeutically effective amount of a cholesterol reducing agent such as an HMG-CoA reductase inhibitor in combination with a platelet aggregation inhibitor which is useful for inhibiting platelet aggregation, for inhibiting the formation of thrombotic occlusions, and for treating, preventing and reducing the risk of occurrence of cardiovascular and cerebrovascular events and related vaso-occlusive disorders.
Inventors
- 👤 Robert J. Gould
- 👤 Steven A. Nichtberger
- 👤 Patricia A. Rhymer
- 👤 Lars Olofsson
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 07:42
CPC Classifications
A; A61; A61K; A61K45/00; A61K45/06
Claims Analysis
Total Claims: 32
Claim 1
Independent Claim
27 words
A pharmaceutical composition comprising a platelet aggregation inhibitor selected from the group consisting of ticlopidine, clopidogrel, and dipyridamole, an HMG-CoA reductase inhibitor and a pharmaceutically acceptable carrier.
Claim 2
Dependent Claim
27 words
A pharmaceutical composition comprising a platelet aggregation inhibitor selected from the group consisting of ticlopidine, clopidogrel, and dipyridamole, an HMG-CoA reductase inhibitor and a pharmaceutically acceptable carrier.
Claim 3
Dependent Claim
29 words
The composition of claim 1 wherein the HMG-CoA reductase inhibitor is selected from lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, cerivastatin and the pharmaceutically acceptable lactone, salt and ester forms thereof.
Claim 4
Dependent Claim
24 words
The composition of claim 2 wherein the HMG-CoA reductase inhibitor is selected from lovastatin and simvastatin and the pharmaceutically acceptable salts and esters thereof.
Claim 5
Dependent Claim
29 words
A pharmaceutical composition made by combining a platelet aggregation inhibitor selected from the group consisting of ticlopidine, clopidogrel, and dipyridamole, an HMG-CoA reductase inhibitor and a pharmaceutically acceptable carrier.
Claim 6
Dependent Claim
29 words
A pharmaceutical composition made by combining a platelet aggregation inhibitor selected from the group consisting of ticlopidine, clopidogrel, and dipyridamole, an HMG-CoA reductase inhibitor and a pharmaceutically acceptable carrier.
Claim 7
Dependent Claim
32 words
A process for making a pharmaceutical composition comprising combining a platelet aggregation inhibitor selected from the group consisting of ticlopidine, clopidogrel, and dipyridamole, an HMG-CoA reductase inhibitor and a pharmaceutically acceptable carrier.
Claim 8
Dependent Claim
32 words
A process for making a pharmaceutical composition comprising combining a platelet aggregation inhibitor selected from the group consisting of ticlopidine, clopidogrel, and dipyridamole, an HMG-CoA reductase inhibitor and a pharmaceutically acceptable carrier.
Claim 9
Dependent Claim
24 words
A kit comprised of an HMG-CoA reductase inhibitor in an oral dosage formulation and a platelet aggregation inhibitor in a separate oral dosage formulation.
Claim 10
Dependent Claim
24 words
A kit comprised of an HMG-CoA reductase inhibitor in an oral dosage formulation and a platelet aggregation inhibitor in a separate oral dosage formulation.
Claim 11
Dependent Claim
32 words
The kit of claim 6 wherein the HMG-CoA reductase inhibitor is selected from lovastatin and simvastatin, and the platelet aggregation inhibitor is selected from the group consisting of ticlopidine, clopidogrel, and dipyridamole.
Claim 12
Dependent Claim
23 words
The kit of claim 6 wherein the HMG-CoA reductase inhibitor is selected from lovastatin and simvastatin, and the platelet aggregation inhibitor is aspirin.
Claim 13
Independent Claim
79 words
A method for reducing the risk of developing a condition selected from the group consisting of: acute coronary ischemic syndrome, thrombosis, thromboembolism, thrombotic occlusion and reocclusion, restenosis, first or subsequent Q-wave myocardial infarction, transient ischemic attack, and first or subsequent thrombotic stroke comprising administration of a therapeutically effective amount of an HMG-CoA reductase inhibitor in combination with a therapeutically effective amount of a platelet aggregation inhibitor to a mammal at risk of developing one or more of said conditions.
Claim 14
Independent Claim
79 words
A method for reducing the risk of developing a condition selected from the group consisting of: acute coronary ischemic syndrome, thrombosis, thromboembolism, thrombotic occlusion and reocclusion, restenosis, first or subsequent Q-wave myocardial infarction, transient ischemic attack, and first or subsequent thrombotic stroke comprising administration of a therapeutically effective amount of an HMG-CoA reductase inhibitor in combination with a therapeutically effective amount of a platelet aggregation inhibitor to a mammal at risk of developing one or more of said conditions.
Claim 15
Dependent Claim
20 words
The method of claim 9 wherein the platelet aggregation inhibitor is selected from the group consisting of ticlopidine and clopidogrel.
Claim 16
Dependent Claim
20 words
The method of claim 9 wherein the platelet aggregation inhibitor is selected from the group consisting of aspirin and dipyridamole.
Claim 17
Dependent Claim
13 words
The method of claim 9 wherein the condition is acute coronary ischemic syndrome.
Claim 18
Dependent Claim
17 words
The method of claim 9 wherein the condition is selected from thrombosis, thromboembolism, thrombotic occlusion and reocclusion.
Claim 19
Dependent Claim
10 words
The method of claim 9 wherein the condition is restenosis.
Claim 20
Dependent Claim
12 words
The method of claim 9 wherein the condition is Q-wave myocardial infarction.
Claim 21
Dependent Claim
12 words
The method of claim 9 wherein the condition is transient ischemic attack.
Claim 22
Dependent Claim
11 words
The method of claim 9 wherein the condition is thrombotic stroke.
Claim 23
Independent Claim
49 words
A method for treating a cardiovascular event selected from acute coronary ischemic syndrome and Q-wave myocardial infarction comprising administration of a therapeutically effective amount of an HMG-CoA reductase inhibitor in combination with a therapeutically effective amount of a platelet aggregation inhibitor to a mammal in need of such treatment.
Claim 24
Independent Claim
49 words
A method for treating a cardiovascular event selected from acute coronary ischemic syndrome and Q-wave myocardial infarction comprising administration of a therapeutically effective amount of an HMG-CoA reductase inhibitor in combination with a therapeutically effective amount of a platelet aggregation inhibitor to a mammal in need of such treatment.
Claim 25
Dependent Claim
22 words
The method of claim 18 wherein the platelet aggregation inhibitor is selected from the group consisting of ticlopidine, clopidogrel, aspirin and dipyridamole.
Claim 26
Independent Claim
38 words
A method for inhibiting platelet aggregation comprising administration of a therapeutically effective amount of a platelet aggregation inhibitor in combination with a therapeutically effective amount of an HMG-CoA reductase inhibitor to a mammal in need of such treatment.
Claim 27
Independent Claim
38 words
A method for inhibiting platelet aggregation comprising administration of a therapeutically effective amount of a platelet aggregation inhibitor in combination with a therapeutically effective amount of an HMG-CoA reductase inhibitor to a mammal in need of such treatment.
Claim 28
Dependent Claim
27 words
The method of claim 20 wherein the platelet aggregation inhibitor is selected from the group consisting of a glycoprotein IIb/IIIa receptor antagonist, ticlopidine, clopidogrel, aspirin and dipyridamole.
Claim 29
Dependent Claim
19 words
The method of claim 9 wherein the platelet aggregation inhibitor and the HMG-CoA reductase inhibitor are both administered orally.
Claim 30
Dependent Claim
24 words
The method of claim 9 wherein the platelet aggregation inhibitor and the HMG-CoA reductase inhibitor are both administered in a single oral dosage composition.
Claim 31
Dependent Claim
34 words
The method of claim 9 wherein the HMG-CoA reductase inhibitor is selected from the group consisting of lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin and cerivastatin and the pharmaceutically acceptable lactone, salt and ester forms thereof.
Claim 32
Dependent Claim
28 words
The method of claim 24 wherein the HMG-CoA reductase inhibitor is selected from the group consisting of lovastatin and simvastatin and the pharmaceutically acceptable salts and esters thereof.
References Cited (Backward Citations)
US5140012A
Cited
WO1995013063A1
Cited
EP0671171A1
Cited
US5674893A
Cited
US6235706B1
Cited
US6251852B1
Cited
WO1999047123A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2005-06-10 | 2005-12-10 | 2006-06-11 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2009-06-10 | 2009-12-10 | 2010-06-11 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2013-06-10 | 2013-12-10 | 2014-06-11 | $7700.00 | Window Closed / Lapsed |